Xie Wei, Zhang Hanzhong, Chen Jian, Wang Ying
Department of Otorhinolaryngology, Wuxi Traditional Chinese Medicine Hospital, Wuxi 214071, China; Email:
Department of Otorhinolaryngology, Wuxi Traditional Chinese Medicine Hospital, Wuxi 214071, China.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015 Aug;50(8):641-5.
To evaluate the efficacy and safety of rush immunotherapy (RIT) for patients with persistent allergic rhinitis (AR).
In this study, a total number of thirty three (33) patients who suffered mite allergic rhinitis were included. These patients completed one year subcutaneous immunotherapy (SCIT). Using RIT, the patients underwent the incremental dose phase in a week instead of 15 weeks in a conventional treatment procedure. The symptom scores, visual analog scale (VAS), appropriate medication score, total blood serum IgE, dermatophagoides pteronyssinus specificity IgG4, mite allergy skin prick test (SPT), dermatophagoides farinae nasal provocation test (NPT) and the incidence of adverse reactions were used to evaluate the efficiency and safety of RIT.
After one year SCIT treatment, the symptom score and VAS scores were significantly decreased, the corresponding medication usage was significantly reduced (8.91 ± 1.84, 20.64 ± 6.99 vs. 4.97 ± 2.92, 11.94 ± 7.21, t value was 9.15, 7.11, both P < 0.001) and the cutaneous reactions to mite allergen were significantly decreased (P < 0.001) as well. However, dermatophagoides pteronyssinus-specific serum IgG4 increased significantly (Z = -4.517, P < 0.001). The concentration of dermatophagoides farinae nasal provocation test (NPT) was significantly increased. After the treatment, the number of patients who had positive reactions to high concentration nasal provocation test (NPT) increased (χ² = 1.93, P = 0.38). During the treatment, all the patients experienced local reactions, and specifically there were four patients got general reactions.
RIT is safe and effective. It shortened the incremental dose phase remarkably. NPT is a good indicator for diagnosing allergic rhinitis and evaluating the efficacy of the treatment.
评估快速免疫疗法（RIT）对持续性变应性鼻炎（AR）患者的疗效和安全性。
本研究纳入了33例患有螨性变应性鼻炎的患者。这些患者完成了一年的皮下免疫疗法（SCIT）。采用RIT，患者在一周内完成递增剂量阶段，而不是传统治疗程序中的15周。使用症状评分、视觉模拟量表（VAS）、适当用药评分、血清总IgE、屋尘螨特异性IgG4、螨过敏皮肤点刺试验（SPT）、粉尘螨鼻激发试验（NPT）以及不良反应发生率来评估RIT的有效性和安全性。
经过一年的SCIT治疗后，症状评分和VAS评分显著降低，相应的药物使用量显著减少（8.91±1.84，20.64±6.99 vs. 4.97±2.92，11.94±7.21，t值分别为9.15、7.11，P均<0.001），对螨过敏原的皮肤反应也显著降低（P<0.001）。然而，屋尘螨特异性血清IgG4显著升高（Z=-4.517，P<0.001）。粉尘螨鼻激发试验（NPT）的浓度显著升高。治疗后，对高浓度鼻激发试验（NPT）呈阳性反应的患者数量增加（χ²=1.93，P=0.38）。治疗期间，所有患者均出现局部反应，具体有4例患者出现全身反应。
RIT安全有效。它显著缩短了递增剂量阶段。NPT是诊断变应性鼻炎和评估治疗效果的良好指标。
